TSDS | Target-Scoped Decision System
Most targets;
and most molecules against them - should not proceed.
TSDS is a governed target-to-asset decision system for difficult drug discovery programs. It begins with target permission and extends into molecule-level progression, helping teams decide which targets, molecules, and execution paths should proceed, pause, or stop.
Constraint precedes selection. Evidence governs progression.
Failure Begins Before the Molecule Fails
Weak Biology
Biology that can't support durable meaningful impact
FALSE TRACTABILITY
The problem is harder then it appears
MOLECULE DRIFT
Program drift off-intent without clear correction.
TSDS does not select.
IT ELIMINATES
Only what survives constraint and evidence is allowed forward.
TWO CONNECTED DECISION LAYERS
01.
TARGET PERMISSION
- Is the biology credible and compelling?
- Can constraints be survived?
- Is the modality fit-for-purpose?
- Can the outcome be measured?
02.
MOLECULE PROGRESSION
- Which molecules should proceed?
- Which should be held for more data?
- Which should stop now?
- Which require re-baselining?
A Target may earn permission. Individual molecules still have to earn progression.
FROM TARGET PERMISSION TO ASSET PROGRESSION.
TARGET PERMISSION
MOLECULE SET
EVIDENCEMAPPING
PROGRESSIONDECISION
EXECUTIONWRITE-BACK
DECISION STATES
PROCEED
Strong Evidence
Advance
forward
PAUSE
Insufficient
Evidence
Gather more
STOP
Unrecoverable
Risk
Do not advance
PARTNER-ONLY
Requires external co-development
WHAT A TSDS ENGAGEMENT PRODUCES.
TARGET PERMISSION
A clear evidence-backed permission decision.
MOLECULE PROGRESSION MAP
A lane-level view of decisions and rationale.
EVIDENCE MAP
Evidence links, quality and sufficiency.
CONSTRAINT REGISTER
Explicit Constraints and survivability thresholds.
DECISION RECEIPTS
Immutable records of decisions clear evidence-backed permission decision.
BOARD DECISION SHEET
Executive ready summary for governance review.